Drugs / B63521^11 gp120
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04041674 | Mar → Sep 2022 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B63521^11 gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04041674 ↗ |
| Modality | Protein / enzyme biologic | “B63521\^11 gp120 and IHV01 gp120 Env Proteins” NCT04041674 ↗ |
| Route | Intramuscular | “150 mcg of B63521\^11 gp120 plus 150 mcg of IHV01, each by IM injection” NCT04041674 ↗ |